Login to Your Account

Biogen adopts late-stage Alkermes MS drug in $228M deal

By Michael Fitzhugh
Staff Writer

Monday, November 27, 2017

Biogen Inc. is snapping up global rights to Alkermes plc's phase III ALKS-8700, a prodrug of the active metabolite in Tecfidera, for $28 million up front, potential milestone payments of up to $200 million, and royalties.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription